Christina Ackermann - 14 May 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Director
Signature
/s/ Andrew Fisher, Attorney-in-fact for Christina Ackermann
Issuer symbol
VRNA
Transactions as of
14 May 2025
Net transactions value
-$260,248
Form type
4
Filing time
16 May 2025, 16:30:26 UTC
Previous filing
29 Apr 2025
Next filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ACKERMANN CHRISTINA Director 3 MORE LONDON RIVERSIDE, LONDON, UNITED KINGDOM /s/ Andrew Fisher, Attorney-in-fact for Christina Ackermann 16 May 2025 0001681871

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Options Exercise $77,352 +40,000 +96% $1.93 81,880 14 May 2025 Direct F1
transaction VRNA Ordinary Shares Sale $337,600 -40,000 -49% $8.44 41,880 14 May 2025 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRNA Share Options (Right to Buy) Options Exercise $0 -40,000 -17% $0.000000 200,000 14 May 2025 Ordinary Shares 40,000 $1.93 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into on February 12, 2025.
F3 The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $8.3894 to $8.5688 per Ordinary Share, inclusive (or $67.115 to $68.55 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4 Consists of 41,880 Ordinary Shares represented by 5,235 ADSs.
F5 The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.
F6 The option is fully vested.